Collaboration - October 4, 2017
Turku Science Park has started as the coordinator of NOME
The Nordic Mentor Network for Entrepreneurship (NOME) is a mentoring program that helps Nordic startups to grow and internationalize. NOME matches Nordic startups with highly skilled volunteer professionals to help them reach their goals and technology milestones. “The goal is simple: to help the very best biotech and medtech startups in the Nordics to become the next growth successes. […]
Collaboration - September 19, 2017
A taste of Nordic strength in life science
NLSDays 2017 took place in a windy and rainy Medicon Valley, but with a warm and collaborative atmosphere among its participants. This year’s Nordic Life Science Days, going on its fifth year, showcased Nordic strength within life science, from small startups to big pharma, and within both business know-how and scientific expertise. But it also showcased Nordic strength […]
Collaboration - September 13, 2017
NLSDays has begun with super sessions and a startup challenge
Nordic Life Science is attending the NLSDays 2017, come by our booth A07 or grap a copy of our most recent issue! “Everything is set up to facilitate networking. We are making it easy for people to meet face-to-face in a secure environment. There is an online platform, EBD Group partnering system PartneringONE, to help people set […]
Collaboration - September 11, 2017
Immunovia collaborates with Lund University
Immunovia announces a collaboration with the researchers at Lund University Diabetes Centre (LUDC) to validate the company´s biomarker signature in high risk group of newly-onset type 2 diabetics (NoD) patients over the age of 50. The risk of these patients to develop pancreatic cancer is over 8 times greater than that of the general population. […]
Collaboration - September 8, 2017
Danish Gubra collaborates with Boehringer Ingelheim
Boehringer Ingelheim and Gubra announce a collaboration and license agreement for the development of novel peptide compounds to treat obesity. The collaboration will bring together Gubra’s expertise in the design, synthesis, characterization and in in vivo testing of therapeutic peptides with Boehringer Ingelheim’s expertise in the development of innovative medicines for patients with cardiometabolic disease. It further […]
Collaboration - August 29, 2017
AstraZeneca, Takeda collaborates on Parkinson’s disease drug
AstraZeneca and Takeda Pharmaceutical have entered an agreement to jointly develop and commercialise MEDI1341, an alpha-synuclein antibody currently in development as a potential treatment for Parkinson’s disease (PD). Alpha-synuclein (α-synuclein) is an aggregation-prone protein that contributes to the development of PD. This protein is the major constituent of Lewy bodies, which are pathological protein aggregates […]
